Crinetics to be acquired by Vertex for $10.0B
Vertex Pharmaceuticals agreed to acquire Crinetics for $85 per share. Net product revenue for the quarter was $24.0 million.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day